Heart Failure With Preserved Ejection Fraction (HFPEF)
54
21
22
15
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.9%
1 terminated out of 54 trials
93.8%
+7.2% vs benchmark
15%
8 trials in Phase 3/4
33%
5 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (54)
ELEVATE-HFpEF Clinical Study
Changes in Intramyocardial Fat Assessed by Cardiac CT Before and After Bariatric Surgery and Their Relationship With Cardiac Diastolic Function
Coronary Artery Stents in Heart Failure With Preserved Ejection Fraction
The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction
AI-based Echocardiography for Detection of Cardiac Amyloidosis
Intracranial Pressure and a Potential Vicious Circle of Atrial Fibrillation in HFpEF
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
PREACTIVE: Preconditioning Exercise Intervention to Improve Symptoms and Quality of Life in Comorbid Atrial Fibrillation and HFpEF
Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR
Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?
The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program
CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction
The Use of Advanced Imaging in HFpEF
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
Data-Driven Phenotyping in Heart Failure With Preserved Ejection Fraction
The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF
Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication